Semantic Scholar uses AI to extract papers important to this topic.
BackgroundSaroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an… Expand Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions… Expand Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD), the absence of approved therapies is… Expand Introduction: Diabetes and dyslipidemia are commonly associated modifiable risk factors for cardiovascular diseases. Majority of… Expand Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and… Expand Cardiovascular risk reduction is an important issue in the management of patients with Type 2 diabetes mellitus. Peroxisome… Expand The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the… Expand BACKGROUND
Dyslipidemia due to diabetes is characterized by hypertriglyceridemia and reduced levels of high-density lipoprotein… Expand Background: Dual PPARα/γ can improve both metabolic effects and minimized the side effects caused by either PPARα or PPAR… Expand Background and ObjectivesDyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus… Expand